SCHEMBL2676362

SCHEMBL2676362

Cc1c(C(=O)O)c2cccc(F)c2c(=O)n1-c1cccc(F)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.51
GAA P10253 1/20 0.41
GFER P55789 1/20 0.41
KDM4E B2RXH2 2/20 0.41
MAPT P10636 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
ATM Q13315 1/20 0.41
HPD P32754 2/20 0.41
TP53 P04637 1/20 0.39
THRB P10828 1/20 0.39
PTGFR P43088 1/20 0.38
METAP2 P50579 1/20 0.38
MPI P34949 1/20 0.38
ALDH1A1 P00352 1/20 0.38
TSHR P16473 1/20 0.38
DHFR P00374 1/20 0.38
DHODH Q02127 1/20 0.38
ALKBH5 Q6P6C2 1/20 0.38
PTGS2 P35354 1/20 0.38
TGM2 P21980 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2677224 0.90 GAA (0.48) NOTUMGAAGFERKDM4EMAPT
SCHEMBL2676694 0.88 NOTUM (0.44) NOTUMGAAGFERKDM4EMAPT
SCHEMBL1717732 0.86 NOTUM (0.54) NOTUMGAAGFERKDM4EMAPT
SCHEMBL1550877 0.82 ALOX12 (0.46) GAAGFERKDM4EMAPTL3MBTL1
SCHEMBL2675354 0.82 NOTUM (0.48) NOTUMGAAGFERKDM4EMAPT
SCHEMBL1550598 0.82 KMT2A (0.37) NOTUMGAAGFERKDM4EMAPT
SCHEMBL1551060 0.81 GAA (0.36) NOTUMGAAGFERKDM4EMAPT
SCHEMBL2676327 0.81 GAA (0.50) NOTUMGAAGFERKDM4EMAPT
SCHEMBL4281013 0.81 PTGFR (0.36) NOTUMGAAGFERKDM4EMAPT
SCHEMBL4281001 0.80 DHODH (0.36) GAAGFERKDM4EMAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US claimed
EP-2150534-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. Lundbeck A/S (DK) 2010-02-10 EP claimed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US claimed
WO-2008131779-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2008-11-06 WO claimed
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
EP-2150534-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. Lundbeck A/S (DK) 2010-02-10 EP disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed
WO-2008131779-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 NOTUM 4527/4885GAA 2229/4885GFER 3896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.